Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Jan 7, 2013; 19(1): 72-77
Published online Jan 7, 2013. doi: 10.3748/wjg.v19.i1.72
Published online Jan 7, 2013. doi: 10.3748/wjg.v19.i1.72
Table 1 Patient characteristics n (%)
| Group A | Group B | Group C | P value | |
| Number of patients | 25 | 54 | 107 | |
| Age (yr) | 0.08 | |||
| Median | 64 | 66 | 68 | |
| Range | 47-81 | 35-84 | 24-89 | |
| Gender | 0.20 | |||
| Male | 11 (44) | 28 (52) | 66 (62) | |
| Female | 14 (56) | 26 (48) | 41 (38) | |
| ECOG performance score | 0.12 | |||
| 0 | 10 (40) | 13 (24) | 46 (43) | |
| 1 | 12 (48) | 37 (69) | 50 (47) | |
| 2-3 | 3 (12) | 4 (7) | 11 (10) | |
| Primary biliary site | 0.47 | |||
| Gallbladder | 14 (56) | 22 (41) | 46 (43) | |
| Intra-hepatic bile duct | 5 (20) | 21 (39) | 40 (37) | |
| Extra-hepatic bile duct | 6 (24) | 9 (16) | 20 (19) | |
| Ampulla of Vater | 0 (0) | 2 (4) | 1 (1) | |
| Disease status | 0.76 | |||
| Locally advanced | 6 (24) | 15 (28) | 24 (22) | |
| Metastatic | 19 (76) | 39 (72) | 83 (78) |
Table 2 Regimens for first-line and second-line treatment
| First-line treatment | |
| Group A (n = 25) | |
| 5-fluorouracil + radiation | 5 |
| 5-fluorouracil ia + radiation | 2 |
| 5-fluorouracil + cisplatin + radiation | 1 |
| 5-fluorouracil ia | 1 |
| 5-fluorouracil + doxorubicin + mitomycin C ia | 1 |
| 5-fluorouracil + cisplatin | 3 |
| 5-fluorouracil + doxorubicin + mitomycin C | 1 |
| Uracil-tegafur | 2 |
| Gemcitabine | 9 |
| Group B (n = 54) | |
| 5-fluorouracil + radiation | 2 |
| 5-fluorouracil ia + radiation | 2 |
| Uracil-tegafur + radiation | 1 |
| 5-fluorouracil | 1 |
| 5-fluorouracil + doxorubicin + mitomycin C | 2 |
| Gemcitabine | 25 |
| S-1 | 20 |
| Gemcitabine + cisplatin | 1 |
| Group C (n = 107) | |
| Gemcitabine + S-1 | 62 |
| Gemcitabine | 44 |
| S-1 | 1 |
| Second-line treatment | |
| Group A (n = 6) | |
| Gemcitabine | 2 |
| Gemcitabine ia | 1 |
| 5-fluorouracil + radiation | 1 |
| S-1 | 1 |
| Uracil-tegafur | 1 |
| Group B (n = 27) | |
| Gemcitabine | 14 |
| S-1 | 9 |
| S-1 + interferon-α | 1 |
| 5-fluorouracil | 2 |
| Mitomycin C | 1 |
| Group C (n = 51) | |
| Gemcitabine + cisplatin | 28 |
| Gemcitabine | 6 |
| S-1 | 13 |
| Cisplatin ia | 1 |
| 5-fluorouracil + interferon-α | 1 |
| Irinotecan | 1 |
| Uracil-tegafur | 1 |
- Citation: Sasaki T, Isayama H, Nakai Y, Takahara N, Sasahira N, Kogure H, Mizuno S, Yagioka H, Ito Y, Yamamoto N, Hirano K, Toda N, Tada M, Omata M, Koike K. Improvement of prognosis for unresectable biliary tract cancer. World J Gastroenterol 2013; 19(1): 72-77
- URL: https://www.wjgnet.com/1007-9327/full/v19/i1/72.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i1.72